US-based Mount Sinai Medical Center has started a clinical trial to evaluate Heart Test Laboratories’ (HTL’s) MyoVista heart screening device.

The device incorporates HTL’s patented technology for the early detection of heart disease.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial will evaluate indications of MyoVista to identify coronary arterial disease (CAD) compared to computed tomographic coronary angiography (CTA) and myocardial dysfunction in patients without CAD compared to echocardiography.

Cardiac Ultrasound Research and Core Lab director Dr Partho Sengupta is principal investigator of the study, which will enroll 200 patients. The trial is expected to take 12 – 24 months to completely evaluate the heart screening device.

In the US, heart disease is the leading cause of death and is responsible for one in every four deaths, which is approximately 600,000 per year.

Existing electrocardiography (ECG) technology is generally not considered effective for use on asymptomatic patients.

"Featuring a 15.6in high resolution touchscreen, the device can be used in primary care and hospital environments."

Heart Test Laboratories CEO Mark Hilz said: "Mount Sinai is one of the most respected medical institutions in the world and has a strong reputation for research along with being recognised as a centre of excellence in cardiology.

"Our goal is to save lives and save healthcare dollars by both finding people with heart disease much earlier, and reducing expensive cardiac testing on people that do not require treatment."

MyoVista, which offers two tests in one, uses 12-lead resting protocols to provide an ECG test that integrates interpretive analysis and proprietary informatics to enable the identification of heart disease at an early stage.

The device also provides additional information, allowing physicians to refer patients to undergo further diagnostic testing and treatment.

Featuring a 15.6in high resolution touchscreen, the device can be used in primary care and hospital environments.

The software on MyoVista deploys a series of algorithms, which have been designed using comparative analysis of a 50,000 patient database used for research and development purposes.

Image: MyoVista device enables the early detection of heart disease. Photo: courtesy of Heart Test Labs.